1. Home
  2. CNVS vs LUNG Comparison

CNVS vs LUNG Comparison

Compare CNVS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cineverse Corp.

CNVS

Cineverse Corp.

HOLD

Current Price

$2.90

Market Cap

54.7M

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.26

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNVS
LUNG
Founded
2000
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Industrial Specialties
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.7M
57.9M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
CNVS
LUNG
Price
$2.90
$1.26
Analyst Decision
Buy
Buy
Analyst Count
1
7
Target Price
$9.00
$5.38
AVG Volume (30 Days)
119.3K
364.8K
Earning Date
02-17-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
108.99
7.64
EPS
N/A
N/A
Revenue
$78,181,000.00
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
$84.42
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
59.13
8.01
52 Week Low
$1.77
$1.13
52 Week High
$7.39
$3.88

Technical Indicators

Market Signals
Indicator
CNVS
LUNG
Relative Strength Index (RSI) 64.12 37.02
Support Level $2.34 $1.19
Resistance Level $2.93 $1.67
Average True Range (ATR) 0.18 0.11
MACD 0.05 -0.04
Stochastic Oscillator 58.07 7.07

Price Performance

Historical Comparison
CNVS
LUNG

About CNVS Cineverse Corp.

Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: